PolarityTE (NASDAQ:PTE) reported quarterly losses of $(0.75) per share. This is a 66.67 percent increase over losses of $(2.25) per share from the same period last year.
Candel Therapeutics Announces Interim Data From Randomized Phase 2 Clinical Trial Of CAN-2409 In Non-Metastatic Pancreatic Cancer
Updated positive interim data showed notable improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in control group in borderline resectable
